新型 SyncroPatch 384 是一种革命性的全自动膜片钳系统，由集成有最先进的液体处理系统 Biomek i5 的膜片钳模块组成。 使用 384 通道放大器和一个 384通道移液头，所有384 个细胞都被并行记录，从而产生每天 20,000 个数据点的通量。得益于其易用性和开放式设计，SyncroPatch 384 支持完全自动化并集成到 HTS 环境中。

但 SyncroPatch 384 不仅仅是一个高通量筛选系统，而且可以在您的所有电生理学项目中实施，无论您的通量需求如何。 32 孔操作模式非常适合较小的筛选项目和学术研究，并充分利用了经济实惠的NPC-384芯片。 以 32 的倍数选择您需要并行记录的孔数，您可以在几天内使用剩余的孔。 或者，您可以使用 SyncroPatch 384 进行长达8 小时的无人值守模式的全自动实验。卓越的数据质量和灵活性使 SyncroPatch 384 成为全球制药公司、CRO 和学术机构等首选的384通道全自动膜片钳系统。

主要特征

• • 千兆级封接记录
• 
  
• • 384孔平行记录
• 
  
• • 32孔模式适用于较少的化合物筛选和研究项目
• 
  
• • 通常成功率达到>85%
• 
  
• • 用于快速脱敏配体门控离子通道的快速外液更换（高达110 μl/s）
• 
  
• • 记录时的內液灌流——通过內液激活通道，例如钙激活K+通道。
• 
  
• • 高级温度控制可以使实验过程中降低或升高的温度（范围10-37°C）标准化
• 
  
• • 具有电流钳功能的基本特点
• 
  
• • 单孔芯片用于高表达细胞系，多孔芯片用于低表达细胞系。 所有芯片都是通过室内质控生产
• 
  
• • 可以收集样品数据进行量效曲线分析
• 
  
• • 受益于卓越的服务和技术支持

PatchControl 384

• 
• PatchControl 384是一个功能强大的图形用户界面，用于直观、快速、轻松地设置电压协议和实验参数。记录井根据用户定义的质量标准（例如密封电阻、串联电阻或电容）进行可视化和颜色编码。单击鼠标一次，视图切换到在线分析结果，例如I/V曲线或浓度响应曲线。

DataControl 384: The Analysis Software

• DataControl 384用于可视化和分析PatchControl 384数据，采用用户定义的数据分析模板。结果（自动IC50、EC50、IV关系图生成）、复合信息和质量控制参数以用户定义的导出格式一起导出，自动生成pdf报告，并为进一步的数据库集成准备数据。这一过程简单、直观且快速完成。
• 
  

NPC-384

NPC-384芯片是SyncroPatch 384的高性价比和高质量耗材。它在慕尼黑的Nanion总部内部生产，质量有保证。可提供不同类型的NPC-384芯片，应根据单元大小和应用选择。带有贴片孔的硼硅酸盐玻璃载玻片封装在384孔板中形成孔，在孔板中输送电流和外部溶液。芯片的设计允许在实验过程中灌注内部溶液。

每个NPC-384芯片包含384个记录室。这些站点可以一次全部使用或以32孔模式使用，芯片的部分可以以32的倍数使用，其余部分可以在几天内使用，成功率不会降低。剩下的零件使用了几天，成功率没有降低。SyncroPatch 384上可以测量一个芯片，机器人中可以堆放25个芯片，用于无人值守的实验。芯片的开放式设计使样品采集和化合物浓度的后续验证成为可能。另外,，内部或外部解决方案的交换次数是无限的。NPC-384芯片可作为GOhm密封的单孔购买，也可作为多孔购买，以增加测量电流振幅并提高成功率。

Available chip types

• "NPC-384, 1x medium resistance": One hole per well (Order # 221102)
• "NPC-384, 1x medium resistance plus": One hole per well (Order # 221104)
• "NPC-384, 4x medium resistance": 4 holes per well (Order # 221402)
• "NPC-384, 1x high resistance": One hole per well (Order # 221101)
• "NPC-384, 4x high resistance": 4 holes per well (Order # 221401)
• "NPC-384, 1x low resistance": One hole per well (Order # 221103)
• "NPC-384, 4x low resistance": 4 holes per well (Order # 221403)
• 
  

• "NPC-384, 8x": 8 holes per well (Order # 221801)
• 
  

应用文献：

32- well mode for smaller screens or academic investigations

SyncroPatch 384 data and applications:

Cells were kindly provided by SB Drug Discovery

An exemplary 32-well Mode Experiment. A small fraction of the chip can be used at a time, which is ideal for smaller compound screens.

Consecutive experiments of 32-wells on the same NPC-384 patch clamp chip over multiple days. Success rate and accurate pharmacology remains stable over 8 days as shown in the figure. Nav1.5 recordings in the presence of increasing Mexiletine concentrations.

AMPA Receptor (GluA2) - Activation by Glutamate

SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2) was activated using different concentrations of glutamate (1 μM - 100 μM). Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384), the whole cell patch methodology and multi-hole chips were used.

The lower two images are displaying screenshots of single cell currents after repetitive glutamate applications:

Left: The same concentration of Glutamate was applied three times.

Right: Four different Glutamate concentrations were applied in a cumulative manner.

CaV1.2 - Current Voltage Relationship

   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Cells kindly provided by Charles River.

CaV1.2 expressed in CHO cells recorded on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). A The screenshot shows the data acquisition and analysis software used on the SyncroPatch 384PE. The online analysis values are shown for a current-voltage experiment. B The raw traces from an example cell elicited by depolarizing steps from -60 mV to 40 mV in 10 mV increments from a holding potential of -80 mV are shown. C The normalized current-voltage plot for an average of 272 cells. A Boltzmann equation fit revealed a V0.5 of activation of -4.8 mV.

CaV1.2 - Pharmacology of Nifedipine, using the CiPA protocol

SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing hCaV1.2/β2/α2δ1 current traces in response to the CiPA voltage step protocol and the corresponing current-voltage relationship plot. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 94%. The IC50 value of Nifedipine was determined as 106 nM.

CaV1.2 - Stable recording from frozen stock cells

SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing hCaV1.2β2/α2δ1 current traces in response to a voltage step protocol and the corresponding current-voltage relationship plot. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 100 %. The cells were used from a frozen cell stock (after induction) and recorded stably for more than 20 minutes. The IC50 value of Nifedipine was determined as 21 nM.

ClC-1 - Current-voltage plot

   SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Activation of hClC-1 tail currents expressed in CHO cells recorded on the SyncroPatch 384i (a predecessor model of SyncroPatch 384). A pre-pulse voltage step to +60 mV was followed by voltage steps from -120 mV to +80 mV for 300 ms (increasing in 20 mV steps) and the tail current was measured at the subsequent step to -100 mV. Out of a possible 384 wells, all 384 wells were used for the IV analysis

ClC-1 – Inhibition by 9-AC

   SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Tail currents of ClC-1 expressed in CHO cells were inhibited by increasing concentration of 9-AC. A single concentration of 9-AC was added to each well and the concentration response curve constructed over multiple wells. The IC50 was calculated to be 6.3 μM for an average of 352 wells. The average current traces are also shown.

GABAA Receptor (α1β2γ2) - Success Rates

   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Bsys.

Statistic of hGABAA α1β2γ2 cells recorded on one NPC-384 1-hole (1x) patch clamp chip. 57 % of the cells on one NPC-384 chip had seal resistance > 1 GOhm at the beginning and 48% at the end of the experiment. Access (RSeries) was good with 80% of cells with RSeries <20 MOhm at the start of the experiment.

GluA2 activation at 110μl/s – speed is key

SyncroPatch 384 data and applications:

Cells were kindly provided by SB Drug Discovery

The AMPA receptor (GluA2) was activated using increasing concentrations of glutamate. Measured on the SyncroPatch 384 the whole cell patch methodology and multi-hole chips were used. The faster you apply the ligand, the shorter is the Time to Peak, this means pipetting speed is relevant for accurate pharmacology. The IC50 of Glutamate at 110 μl/s was 460 μM.

Glycine Receptor (GlyRa1) - Reproducible Current Recordings

   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Glycine-mediated current traces and corresponding time plots from 384 simultaneously recorded HEK cells are shown. Multiple additions of 50 μM Glycine produce very robust current responses with similar peaks, providing best conditions for cumulative pharmacology on one cell.

hERG - Pharmacology at Physiological Temperature using the CiPA Protocol

   SyncroPatch 384/768 PE (a predecessor model of the SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol at 35 degree Celsius. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch clamp methodology (Escin) and multi-hole chips (4 holes per well). The IC50 value of Erythromycin of the peak current was determined as 60.5 μM. 

hERG - Pharmacology using the CiPA Protocol

   SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using whole cell patch clamp methodology and multi-hole chips (4 holes per well). The IC50 value of the following compounds of the peak current was determined as 4.18 μM for Diltiazem, 37.4 nM for Terfenadine, 971 nM for Quinidine, 63 μM for Mexiletine, 431 nM for Verapamil and 4.54 μM for Ranolazine. 

hERG - recordings with great stability using the CiPA step ramp protocol

   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch clamp methodology (Escin) and multi-hole chips (4 holes per well). 

hERG - Stable Recordings with Accurate Pharmacology

   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications: 

Cells were kindly provided by Charles River Laboratories.

Current-voltage relationship of hERG (Kv11.1) expressed in HEK293 is shown along with pharmacology of 4 hERG-active compounds. The current-voltage relationships for all 384 wells (top) using perforated patch (Escin) and multi-hole chips (4 holes per well) are shown. In all 384 wells, a hERG-mediated current was observed with peak amplitude >700 pA at -20 mV. Using a pharmacology voltage protocol, experiments were stable lasting over 20 minutes. Concentration response curves for astemizole, pimozide, cisapride and terfenadine revealed IC50 values consistent with those found in the literature. 

hERG and Temperature Control

SyncroPatch 384 data and applications:

Cells were kindly provided by Charles River Chantest

Cardiac ion channels are recommended to be recorded at Phys. Temp. (ICH S7B Q&A. 2021). On the SyncroPatch 384, measurement site, cells and solutions can be accurately temperature controlled – in the presence of physiological temperatures the hERG current kinetic is changed to a larger slope and higher amplitude.

KCa1.1 (BK) - High throughput study

   SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:

Data kindly provided by Sharan R. Srinivasan1 and Vikram G. Shakkottai1,2

1Department of Neurology, University of Michigan, Ann Arbor, MI 48109;

2Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109.

HEK293 cells stably transfected with BK channels were used to screen over 50,000 compounds, and using clever buffering techniques, targeting only activators of calcium sensitivity for BK channel augmentation. 

KCa3.1 (SK4) - Activation by Perfusion of free internal Calcium

    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software are showing KCa3.1 raw traces and according time plots (online analysis) to a voltage ramp from -120 mV to + 60 mV over 200 ms. The application of internal Ca2+ is indicated by the yellow bar. The current increased upon application of internal Ca2+ reaching a peak within 1-2 min after the start of the perfusion. Five minutes of stable KCa3.1 current was recorded prior the channel was inhibited by cumulative additions of external Ba2+; first partly (1 mM Ba2+) and then completely (5 mM Ba2+). The recording was performed with perfectly high success rates in whole cell configuration on a multi hole chip (4 holes per well) using the SyncroPatch 384PE (a predecessor model of SyncroPatch 384).

Kir2.1 - Pharmacology of Barium

    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing Kir2.1 current traces in response to a voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using the whole cell patch methodology and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was  93%. The IC50 value of Barium was determined as 6.38 μM (Literature: 16.2 μM, Schram et al. Cardiovasc Res. 2003).

KV1.3 - Pharmacology with High Success Rate

   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

Cells were kindly provided by Evotec.

Shown are screenshots of a pharmacology experiment performed with the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). Recordings from 384 KV1.3 expressing CHO cells were performed simultaneously. Original current traces and the peak current over time are displayed. Data are analysed with DataControl384 full analysis tool. With just a few mouse-clicks normalized concentration response curves can be generated. Here, normalized response and the IC50 of Quinidine is shown. Darkening shades of blue indicate increasing compound concentration.